Abstract
The dentate gyrus (DG) is one of only two brain structures known to retain the ability to produce new neurons in adulthood. The functional significance of adult neurogenesis in the DG is not yet well understood, but recent evidence has implicated adult neurogenesis in the etiology and treatment of depression. Elevated stress hormone levels, which are present in some depressed patients and can precipitate the onset of depression, reduce neurogenesis in animal models. Conversely, virtually all antidepressant treatments studied to date, including drugs of various classes, electroconvulsive therapy, and behavioral treatments, increase neurogenesis in the DG. We critically review this literature linking DG neurogenesis with depression, looking to both animal and human studies. We conclude that a reduction in neurogenesis by itself is not likely to produce depression. However, at least some therapeutic effects of antidepressant treatments appear to be neurogenesis-dependent. We review the cellular pathways through which antidepressant drugs boost neurogenesis and present several hypotheses about how DG neurogenesis may be instrumental in the therapeutic effects of these drugs.
Keywords: subgranular zone, long-term potentiation, Emotion, Stress, Hippocampal Atrophy
CNS & Neurological Disorders - Drug Targets
Title: Adult Hippocampal Neurogenesis as Target for the Treatment of Depression
Volume: 6 Issue: 3
Author(s): Michael R. Drew and Rene Hen
Affiliation:
Keywords: subgranular zone, long-term potentiation, Emotion, Stress, Hippocampal Atrophy
Abstract: The dentate gyrus (DG) is one of only two brain structures known to retain the ability to produce new neurons in adulthood. The functional significance of adult neurogenesis in the DG is not yet well understood, but recent evidence has implicated adult neurogenesis in the etiology and treatment of depression. Elevated stress hormone levels, which are present in some depressed patients and can precipitate the onset of depression, reduce neurogenesis in animal models. Conversely, virtually all antidepressant treatments studied to date, including drugs of various classes, electroconvulsive therapy, and behavioral treatments, increase neurogenesis in the DG. We critically review this literature linking DG neurogenesis with depression, looking to both animal and human studies. We conclude that a reduction in neurogenesis by itself is not likely to produce depression. However, at least some therapeutic effects of antidepressant treatments appear to be neurogenesis-dependent. We review the cellular pathways through which antidepressant drugs boost neurogenesis and present several hypotheses about how DG neurogenesis may be instrumental in the therapeutic effects of these drugs.
Export Options
About this article
Cite this article as:
Drew R. Michael and Hen Rene, Adult Hippocampal Neurogenesis as Target for the Treatment of Depression, CNS & Neurological Disorders - Drug Targets 2007; 6 (3) . https://dx.doi.org/10.2174/187152707780619353
DOI https://dx.doi.org/10.2174/187152707780619353 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Subject Index to Volume 3
Current Drug Targets - CNS & Neurological Disorders The Pharmacogenetics of CYP2C9 and CYP2C19: Ethnic Variation and Clinical Significance
Current Clinical Pharmacology Conference Report: Summary Report of the International Association of Neurorestoratology VII Conference: Regulations, Ethics, Science, and the Need of Patients Care in Neurorestoratology
CNS & Neurological Disorders - Drug Targets Synthesis and Evaluation of N-substituted (Z)-5-(Benzo[d][1,3]dioxol-5- ylmethylene)-2-Thioxothiazolidin-4-one Derivatives and 5-Substituted- Thioxothiazolidindione Derivatives as Potent Anticonvulsant Agents
CNS & Neurological Disorders - Drug Targets The Interaction of Zinc Oxide/Green Tea Extract Complex Nanoparticles and its Effect on Monosodium Glutamate Toxicity in Liver of Rats
Current Pharmaceutical Biotechnology GPCR Drug Discovery: Novel Ligands for CNS Receptors
Recent Patents on CNS Drug Discovery (Discontinued) Non-canonical Molecular Targets for Novel Analgesics: Intracellular Calcium and HCN Channels
Current Neuropharmacology Prediction of Disease-Related Genes Based on Hybrid Features
Current Proteomics Caring for Children with Medical Complexity: Definitions, Challenges and Solutions
Current Pediatric Reviews Small Peptide and Protein-based Molecular Probes for Imaging Neurological Diseases
Current Protein & Peptide Science HIV-1 Reactivation Induced by Apicidin Involves Histone Modification in Latently Infected Cells
Current HIV Research Glycosphingolipid Structure and Function in Membranes
Current Organic Chemistry Improving Cognitive Outcome in Cerebral Malaria: Insights from Clinical and Experimental Research
Central Nervous System Agents in Medicinal Chemistry Drug Transport Across the Blood-Brain Barrier and the Impact of Breast Cancer Resistance Protein (ABCG2)
Current Topics in Medicinal Chemistry Synthesis, Antifungal Activity and Carbonic Anhydrase Inhibitory Properties of Cu (II) Bis (3, 4 Dimethoxybenzoate) Bis (Nicotinamide) Dihydrate
Current Enzyme Inhibition A Study of Applications of Machine Learning Based Classification Methods for Virtual Screening of Lead Molecules
Combinatorial Chemistry & High Throughput Screening Synthesis and Biological Evaluation of Novel 2,3-disubstituted Benzofuran Analogues of GABA as Neurotropic Agents
Medicinal Chemistry Curcumin Alleviates Cerebral Ischemia-reperfusion Injury by Inhibiting NLRP1-dependent Neuronal Pyroptosis
Current Neurovascular Research Novel Hybrid Anticonvulsants Derived from Pyrrolidine-2,5-dione Scaffold with Broad Spectrum of Activity in the Preclinical Studies
Current Topics in Medicinal Chemistry Antiepileptic Treatments in Developing Countries
Current Pharmaceutical Design